However, its benefits extend to other related conditions: Type 2 Diabetes Tirzepatide effectively manages blood sugar levels, reducing the risk of diabetes-related complications such as neuropathy, retinopathy, and kidney disease
Ailawadi and colleagues plan to characterize the adverse effect profile of GLP-1 RAs, specifically in patients with IBD
Remember, adding GLP-1 is not a sign of failure, but an effective, evidence-based tool to aid significant, durable weight loss
Beneficiaries may need to meet requirements related to: Age Body mass index, or BMI A prescription for weight loss or maintaining weight reduction Use of the medication along with lifestyle modifications Other qualifying health conditions CMS guidance indicates that the program is designed for beneficiaries seeking GLP-1 medications solely to reduce excess body weight or maintain weight reduction
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
Back Knudsen, LB, Nielsen, PF, Huusfeldt, PO, et al (2000) 'Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration', Journal of Medicinal Chemistry , 43, 1664-69
